All In Biotech

Drug Trial Radar · NCT06694389

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age

Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,457 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,457

Actual

Start

Nov 18, 2024

Primary completion

Nov 17, 2025

Study completion Nov 17, 2025

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Nov 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).

Conditions

  • COVID-19
  • Influenza

Interventions

  • mRNA-1083Biological

    Suspension for injection

  • PlaceboOther

    0.9% sodium chloride suspension for injection

  • Licensed Influenza VaccineBiological

    Aqueous injectable (SC) or suspension for injection (IM)

  • SARS-CoV-2 VaccineBiological

    Suspension for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) AssayTime frame: Day 29
  2. GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)Time frame: Day 29
  3. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Day 1 through 7 days after study injection
  4. Number of Participants With Unsolicited Adverse Events (AEs)Time frame: Day 1 through 28 days after study injection
  5. Number of Participants With Medically Attended Adverse Events (MAAEs)Time frame: Day 1 though Day 181
  6. Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: Day 1 though Day 181
  7. Number of Participants With Serious Adverse Events (SAEs)Time frame: Day 1 through Day 181
  8. Number of Participants With AEs Leading to DiscontinuationTime frame: Day 1 through Day 181

Locations

44 sites in 3 countries. Site status is shown where the registry gives one.

  • Public Health Association.Inc.

    Nagoya, Aichi-ken, Japan

  • Daido Clinic

    Nagoya, Aichi-ken, Japan

  • Tenjin Sogo Clinic

    Fukuoka, Fukuoka, Japan

  • PS Clinic - Internal medicine

    Fukuoka, Fukuoka, Japan

  • Fukuoka Heartnet Hospital

    Fukuoka, Fukuoka, Japan

  • Medical Coporation of Yamazaki Neurotology, Rhinolaryngology Clinical

    Sapporo, Hokkaido, Japan

  • Motomachi Takatsuka Naika Clinic - Internal Medicine

    Yokohama, Kanagawa, Japan

  • Sakurajyuji Medical Corporation Medimesse Sakurajyuji Clinic

    Kumamoto, Kumamoto, Japan

  • Nishi-Kumamoto Hospital

    Kumamoto, Kumamoto, Japan

  • Sato Hospital

    Osaki-shi, Miyagi, Japan

  • Yokoi Medicine Clinic

    Mino, Osaka, Japan

  • Shinwakai Adachi Kyosai Hospital - Internal Medicine

    Adachi-ku, Tokyo, Japan

  • Dojinkinenkai Meiwa Hospital

    Chiyoda-ku, Tokyo, Japan

  • Nihonbashi Sakura Clinic

    Chuo-ku, Tokyo, Japan

  • Tokyo center clinic - Internal medicine

    Chuo-ku, Tokyo, Japan

  • Medical Corporation Asbo Tokyo Asbo Clinic

    Chuo-ku, Tokyo, Japan

  • New Medical Research System Clinic

    Hachioji-shi, Tokyo, Japan

  • Shimamura Memorial Hospital

    Nerima City, Tokyo, Japan

  • Denenchofu Family Clinic

    Ōta-ku, Tokyo, Japan

  • Hillside Clinic Jingumae

    Shibuya-ku, Tokyo, Japan

  • Clinical Research Tokyo Hospital - Clinical Research Center

    Shinjuku, Tokyo, Japan

  • Higashi-Shinjuku Clinic - Internal Medicine

    Shinjuku, Tokyo, Japan

  • Shinei Medical Healthcare Clinic

    Suginami, Tokyo, Japan

  • Souseikai Sumida Hospital

    Sumida-Ku, Tokyo, Japan

  • Seishukai Clinic

    Taito-ku, Tokyo, Japan

  • Metropolitan Clinic - Internal Medicine

    Toshima-ku, Tokyo, Japan

  • Korea University Ansan Hospital

    Ansan-si, South Korea

  • Kyungpook National University Hospital - Infectious Diseases

    Daegu, South Korea

  • Chonnam National University Hospital - Allergology

    Gwangju, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Hallym University Kangnam Sacred Heart Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Ajou University Hospital

    Suwon, South Korea

  • Yonsei University, Wonju Severance Christian Hospital

    Wŏnju, South Korea

  • Kaohsiung Medical University - Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan

  • Kuang Tien General Hospital - Dajia

    Taichung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.